There were no differences in baseline hs-cTnT and NT-proBNP biomarker levels or clinical and biochemical variables at baseline in participants who experienced MACE (angina, myocardial infarction, revascularization, cerebrovascular accident, and cardiovascular mortality) compared to those who did not (Table 4). This evidence concerns the gene NPPB and Stroke.